Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).
The treatment landscape for men with castration-resistant prostate cancer (CRPC) is undergoing significant changes; a redefinition of the respective roles of oncologists and urologists will probably occur. In addition, the advent of the multidisciplinary team or coordinated-care approach, which has been gathering momentum over the last decade, will become not simply a preference but a clear necessity. In the present review, we explore the current wave of new treatments and describe the possibility of more complex approaches to combined therapy. New treatment options include abiraterone acetate, cabazitaxel, MDV3100 (in development), radium-223 (in development) and sipuleucel-T. We also present the traditional roles of the urologist and oncologist in caring for patients with CRPC and discuss how these may change. Compounding the new potential for treatment success, as well as the complexity of therapeutic strategies, is the emergence of novel biomarkers to evaluate treatment efficacy and to assist in patient prognosis. The prospects for successful treatment of patients with CRPC have developed considerably so that these patients may soon have a reasonable expectation of therapeutic efficacy and meaningful extension of their lives.
Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70115, USA. osartor@tulane.edu
A Oliver
AO
Sartor
John M
JM
Fitzpatrick
D000069501:Abiraterone Acetate; D000284:Administration, Oral; D059002:Androgen Receptor Antagonists / Q000008:administration & dosage; D000730:Androstadienes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D008297:Male; D008495:Medical Oncology; D009570:Nitriles; D009919:Orchiectomy; D010166:Palliative Care; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives; D010819:Physician's Role; D011364:Professional Practice; D011471:Prostatic Neoplasms / Q000628:therapy*; D043823:Taxoids / Q000008:administration & dosage; D035703:Therapies, Investigational; D014020:Tissue Extracts / Q000008:administration & dosage; D014572:Urology
D059002:Androgen Receptor Antagonists; D000730:Androstadienes; D001549:Benzamides; D014408:Biomarkers, Tumor; D009570:Nitriles; D043823:Taxoids; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; C552428:cabazitaxel; C511774:sipuleucel-T; C540278:enzalutamide; D000069501:Abiraterone Acetate